FirstWord

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:
  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Research Reports By FirstWord

Found 534 publications
Market Access Impact (US) [CLL] US$ 5,145.00 Jun, 2017
CAR-T Disease Outlook [2017] US$ 8,145.00 Jun, 2017
Breast Cancer: KOL Insight [2017] US$ 8,145.00 Jun, 2017
NPS+ (US) [Melanoma] US$ 2,575.00 Jun, 2017
Medical Affairs in Orphan Drugs US$ 695.00 Jun, 2017
NPS+ (EU5) [Melanoma] US$ 2,575.00 Jun, 2017
Market Access Impact (EU5) [CLL] US$ 5,145.00 Jun, 2017
NASH: KOL Insight [2017] US$ 8,795.00 Jun, 2017
Medical Affairs Reputations (US) [MS] US$ 6,175.00 Jun, 2017
Market Access Impact (US) [RCC] US$ 5,145.00 May, 2017
NPS+ (US) [Asthma/COPD] US$ 2,575.00 May, 2017
Psoriasis [2016]: Bulletin #3 US$ 1,045.00 May, 2017
Market Access Impact (EU5) [RCC] US$ 5,145.00 May, 2017
NPS+ (EU5) [Asthma/COPD] US$ 2,575.00 May, 2017
Prostate Cancer [2016]: Bulletin #2 US$ 1,045.00 May, 2017
How Payers Want to Work With Pharma US$ 2,245.00 May, 2017
COPD [2017] US$ 8,145.00 May, 2017
Ovarian Cancer [2017] US$ 8,145.00 May, 2017
Biosimilars: US Payer Perspectives US$ 2,245.00 Apr, 2017
The Future of Biobetters US$ 2,245.00 Apr, 2017
Market Access Impact (US) [HIV] US$ 5,145.00 Apr, 2017
NPS+ (US) [PsO] US$ 2,575.00 Apr, 2017
Market Access Impact (EU5) [HIV] US$ 5,145.00 Apr, 2017
NPS+ (EU5) [PsO] US$ 2,575.00 Apr, 2017
Rheumatoid Arthritis [2017] US$ 8,145.00 Apr, 2017
Biosimilars in Emerging Markets US$ 2,245.00 Mar, 2017
NPS+ (EU5) [HIV] US$ 2,575.00 Mar, 2017
HNSCC: KOL Insight [2017] US$ 8,145.00 Mar, 2017
1 2 3 4 5 ... 11
Skip to top

Analytics, News & Press-Releases by FirstWord